Renaissance Technologies LLC boosted its position in shares of GlaxoSmithKline plc (NYSE:GSK) by 8.6% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 10,135,200 shares of the pharmaceutical company’s stock after buying an additional 805,800 shares during the quarter. GlaxoSmithKline accounts for approximately 0.4% of Renaissance Technologies LLC’s investment portfolio, making the stock its 28th largest position. Renaissance Technologies LLC owned approximately 0.41% of GlaxoSmithKline worth $407,131,000 at the end of the most recent quarter.
Other hedge funds have also recently made changes to their positions in the company. Cpwm LLC purchased a new stake in shares of GlaxoSmithKline during the third quarter valued at $1,368,000. Allianz Asset Management GmbH purchased a new stake in shares of GlaxoSmithKline during the third quarter valued at $3,093,000. William Blair Investment Management LLC purchased a new stake in shares of GlaxoSmithKline during the third quarter valued at $2,630,000. Diamond Hill Capital Management Inc. lifted its holdings in shares of GlaxoSmithKline by 133.6% during the third quarter. Diamond Hill Capital Management Inc. now owns 429,279 shares of the pharmaceutical company’s stock valued at $17,244,000 after purchasing an additional 245,549 shares during the last quarter. Finally, Eaton Vance Management lifted its holdings in shares of GlaxoSmithKline by 49.3% during the third quarter. Eaton Vance Management now owns 1,916,771 shares of the pharmaceutical company’s stock valued at $76,996,000 after purchasing an additional 633,093 shares during the last quarter. 10.97% of the stock is owned by institutional investors and hedge funds.
GSK has been the subject of several analyst reports. Argus upped their target price on GlaxoSmithKline from $45.00 to $47.00 and gave the company a “buy” rating in a report on Monday, August 20th. Liberum Capital downgraded GlaxoSmithKline from a “buy” rating to a “hold” rating in a report on Thursday, August 30th. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of GlaxoSmithKline in a report on Tuesday, September 25th. Zacks Investment Research raised GlaxoSmithKline from a “hold” rating to a “buy” rating and set a $45.00 target price for the company in a report on Tuesday, September 25th. Finally, Guggenheim initiated coverage on GlaxoSmithKline in a report on Monday, October 8th. They set a “neutral” rating for the company. Thirteen investment analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $43.00.
Shares of GlaxoSmithKline stock opened at $38.34 on Wednesday. The stock has a market capitalization of $103.83 billion, a P/E ratio of 13.31, a price-to-earnings-growth ratio of 2.59 and a beta of 0.81. The company has a debt-to-equity ratio of 6.66, a current ratio of 0.95 and a quick ratio of 0.63. GlaxoSmithKline plc has a 1 year low of $34.52 and a 1 year high of $42.36.
GlaxoSmithKline (NYSE:GSK) last announced its quarterly earnings data on Wednesday, October 31st. The pharmaceutical company reported $0.83 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.86 by ($0.03). The business had revenue of $9.41 billion during the quarter, compared to analysts’ expectations of $10.55 billion. GlaxoSmithKline had a return on equity of 164.99% and a net margin of 5.78%. On average, research analysts forecast that GlaxoSmithKline plc will post 3.01 earnings per share for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, January 10th. Investors of record on Friday, November 16th will be paid a $0.486 dividend. This is an increase from GlaxoSmithKline’s previous quarterly dividend of $0.46. This represents a $1.94 annualized dividend and a yield of 5.07%. The ex-dividend date of this dividend is Thursday, November 15th. GlaxoSmithKline’s dividend payout ratio is currently 67.36%.
TRADEMARK VIOLATION WARNING: “Renaissance Technologies LLC Increases Position in GlaxoSmithKline plc (GSK)” was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this report on another publication, it was illegally copied and republished in violation of US and international copyright & trademark law. The correct version of this report can be accessed at https://www.dispatchtribunal.com/2018/12/05/renaissance-technologies-llc-increases-position-in-glaxosmithkline-plc-gsk.html.
GlaxoSmithKline Company Profile
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.
Read More: Asset Allocation, Balancing Your Investments
Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GlaxoSmithKline plc (NYSE:GSK).
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.